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Introduction
Oral cancer is the fifth most common cancer in the 
world.1 In Taiwan, oral cancers ranked as the sixth 
most prevalent cancer in both sexes and was the 
fourth most common cancer in males in 2006.2 The 
main etiologies of oral squamous cell carcinoma 
(OSCC) in Taiwan are areca quid (AQ) (betel nut, 
Our previous studies showed successful treatment of a series of 36 oral verrucous 
hyperplasia lesions and of an extensive oral verrucous carcinoma with a topical 
5-aminolevulinic acid (ALA)-mediated photodynamic therapy (topical ALA-PDT) pro-
tocol (with a fluence rate of 100 mW/cm2 and a light exposure dose of 100 J/cm2) 
using a 635-nm light-emitting diode (LED) light source. In this case report, we 
tested whether an enhanced topical ALA-PDT protocol (with a fluence rate of 
200 mW/cm2 and a light exposure dose of 200 J/cm2) could be used to treat an 
early invasive oral squamous cell carcinoma (OSCC) with a verrucous appearance of 
the left lower posterior edentulous alveolar mucosa of a 67-year-old male former 
areca-quid chewer and ex-smoker. The main verrucous lesion showed complete 
regression after eight treatments with PDT. However, 10 extra treatments were 
needed to eradicate the multiple residual leukoplakia lesions on the edentulous 
alveolar mucosa. Moderate to severe post-PDT pain was noted during the initial 
eight treatments, and the patient needed analgesics (codeine phosphate, 30 mg 
three times daily) to control the pain. No recurrence of the OSCC lesion was found 
after a follow-up period of 4 years. We suggest that our enhanced topical ALA-PDT 
protocol may have good potential to be used as a treatment of choice for a superfi-
cially invasive OSCC without regional or distant metastasis before the commence-
ment of other effective therapies.
Received: Nov 23, 2009
Accepted: Jan 21, 2010
KEY WORDS:
5-aminolevulinic acid;
early invasive oral cancer;
topical photodynamic
 therapy
Successful treatment of an early invasive 
oral squamous cell carcinoma with topical 
5-aminolevulinic acid-mediated 
photodynamic therapy
Hsin-Ming Chen,1,2,3 Chuan-Hang Yu,2 Hung-Pin Lin,2 Hsiang Yang,3 
Ru-Cheng Kuo,3 Ying-Shiung Kuo,4 Chun-Pin Chiang1,2,3*
1Graduate Institute of Oral Biology, School of Dentistry, National Taiwan University, Taipei, Taiwan
2Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan
3Department of Dentistry, National Taiwan University Hospital, College of Medicine, National Taiwan 
 University, Taipei, Taiwan
4Department of Dentistry, Far Eastern Memorial Hospital, Taipei, Taiwan
ALA-PDT for early oral cancer 37
Areca catechu) chewing, cigarette smoking, and al-
cohol consumption. There are 2 million people who 
habitually chew AQ,3 and approximately 80% of all 
oral cancer deaths are associated with this habit.4 
In Taiwan, oral cancers are usually treated with rad-
ical surgical excision, chemotherapy, and radiother-
apy, separately or in combination. Although various 
treatment modalities are used, the survival rate 
for oral cancer patients in Taiwan remains low. The 
respective 5-year survival rates are 72%, 39%, 27%, 
and 12% for those with stage I, II, III, and IV oral 
cancers.5 The low 5-year survival rate in patients 
with advanced oral cancers suggests the importance 
of early detection and treatment of oral cancers. 
In addition, one of the best strategies to prevent 
oral cancers is to identify the oral cancers at their 
precancerous stages or at as early a stage as pos-
sible and eliminate them to prevent their further 
transformation into oral cancers.
Oral verrucous carcinoma (OVC) is a low-grade 
but usually extensive tumor of the oral mucosa. An 
OVC may develop into an invasive OSCC during its late 
carcinogenic stage. Traditional treatment for OVC 
is total surgical excision that always leads to scar 
formation. Photodynamic therapy (PDT) is another 
effective treatment option for human premalignant 
and malignant lesions because it is noninvasive, is 
well tolerated by patients, can be used repeatedly 
without cumulative side effects, and results in little 
scar formation.6 5-Aminolevulinic acid (ALA) itself 
is not a photosensitizer but serves as the biological 
precursor of the photosensitizer, protoporphyrin IX 
(PpIX), in the heme biosynthesis pathway. PDT with 
topically applied ALA (topical ALA-PDT) is used for 
treatment of human oral premalignant lesions with 
relatively good clinical outcomes.7−14 Our previous 
studies showed successful treatment of 36 oral ver-
rucous hyperplasia (OVH) lesions and an extensive 
OVC with a topical ALA-PDT protocol (with a flu-
ence rate of 100 mW/cm2 and a light exposure dose 
of 100 J/cm2) using a 635-nm light-emitting diode 
(LED) light source.10−15 In this case report, we tested 
the efficacy of an enhanced topical ALA-PDT proto-
col (with a fluence rate of 200 mW/cm2 and a light 
exposure dose of 200 J/cm2) on an early invasive OSCC 
with a verrucous appearance at the buccal gingiva 
of tooth 33 and the edentulous alveolar mucosa of 
the teeth 34−36 region of a 67-year-old male former 
AQ chewer and ex-smoker.
Case presentation
This 67-year-old male patient was referred to our 
outpatient dental clinic for treatment of a verru-
cous lesion measuring about 3 × 1.5 cm on the buc-
cal gingiva of tooth 33 and the edentulous alveolar 
mucosa of the teeth 34−36 region (Fig. 1A). The pa-
tient had hypertension (systolic pressure of 140 mmHg 
and diastolic pressure of 90 mmHg on average) that 
was under drug control. The patient denied having 
any other major systemic diseases. The patient had 
chewed AQ (40−50 quids/day) for 30 years and had 
smoked (20 cigarettes/day) for 40 years. He had quit-
ted chewing AQ 10 years previously, but had only 
quitted smoking 4 months previously. He began to 
notice a verrucous tumor on the left lower posterior 
edentulous alveolar mucosal area 4 months previ-
ously. Although he had quitted smoking 4 months 
previously, the tumor continued to grow to the pres-
ent form and size. During the past 4 months, the 
patient had received no treatment. Based on the size 
and appearance of the lesion, the tentative clinical 
diagnosis was an OVC. However, an incisional biopsy 
taken from the tumor portion of the edentulous al-
veolar mucosa of the tooth 34 area showed an early 
invasive OSCC (Figs. 1B and 1C). Magnetic resonance 
imaging revealed no metastatic lymph nodes in the 
bilateral submandibular, carotid or posterior cervical 
region. In addition, a whole-body bone scan revealed 
no bone metastasis. The patient refused to undergo 
wide surgical excision of the tumor. After discussion 
with the patient, we decided to use an enhanced top-
ical ALA-PDT protocol (with a fluence rate of 200 mW/
cm2 and a light exposure dose of 200 J/cm2) to treat 
him after he provided informed consent.
The treatment course for this patient was the 
same as that for our previous OVH or OVC patients 
as described previously,10−15 except that a twofold 
higher light exposure dose was given to the patient 
in this case. In brief, at the first visit, an oral exami-
nation and incisional biopsy were performed. At the 
second appointment, we did a kinetics study with 
topical ALA using ALA-induced PpIX fluorescence 
spectroscopy and found that the PpIX reached its 
maximum level in the lesional epithelial cells 1.5 
hours after local ALA application. Therefore, the 
subsequent light treatments were set at 1.5 hours 
after topical application of ALA to the lesion. The 
topical ALA-PDT was performed once a week be-
ginning from the patient’s third appointment. On 
the day of treatment, 0.8 mL of 20% ALA was applied 
to the entire tumor upon the patient’s arrival. The 
light treatment was composed of multiple 3-minute 
sessions of irradiation with an LED red light at 635 ± 
5 nm separated with several 3-minute rest periods 
for a total of 1000 seconds (with a fluence rate of 
200 mW/cm2 and a light exposure dose of 200 J/
cm2) which was delivered 1.5 hours after topical 
ALA application. Light treatments were carried out 
under local anesthesia using 2% lidocaine with the 
patient fully conscious. The tip of the LED light de-
vice was kept as close to the surface of the lesion 
as possible. The verrucous lesion showed nearly 
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Fig. 1 Clinical photographs and histologic microphotographs of an early invasive squamous cell carcinoma (SCC) 
lesion. (A) An initial oral verrucous carcinoma-like lesion at the buccal gingiva of tooth 33 and the edentulous alveolar 
mucosa of the teeth 34−36 region before treatment. (B, C) Incisional biopsy of the tumor portion at the edentulous 
alveolar mucosa of the tooth 34 area showing a verrucous carcinoma with early invasion of SCC tumor nests into the 
underlying connective tissue (hematoxylin and eosin stain; B: original magnification ×5, C: original magnification ×25). 
Clinical photographs of the early invasive SCC lesion showing a partial response of the main verrucous lesion after (D) 
three and (E) six treatments of the enhanced topical ALA-PDT, nearly complete regression of the main verrucous 
lesion after (F) eight PDT treatments, multiple residual leukoplakic lesions at the edentulous alveolar mucosa after 
(F) eight and (G) 14 PDT treatments, and complete regression of the lesion after (H) 18 PDT treatments. (H) A white 
lesion of oral submucous fibrosis is still evident at the left buccal mucosa.
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complete regression after eight treatments of the 
enhanced topical ALA-PDT (Figs. 1D−F). However, the 
multiple residual leukoplakia lesions needed 10 extra 
treatments to achieve complete regression (Figs. 
1G and 1H). Because of the severe post-PDT pain, 
codeine phosphate (30 mg/tablet, 1 tablet 3 times/
day) was prescribed for the patient for the former 
eight treatments and acetaminophen (500 mg/tablet, 
1 tablet 4 times/day) was given to the patient for 
the latter 10 treatments after PDT. After comple-
tion of the entire treatment course, the patient was 
followed up once every 2 weeks in the 1st month, 
once every 2 months in the following 6 months, 
and once every 3 months thereafter. No recurrence 
of the lesion was found after a follow-up period of 
4 years.
Discussion
In this case report, we describe treatment of an 
early invasive OSCC on the buccal gingiva of tooth 
33 and the edentulous alveolar mucosa of the teeth 
34−36 region of a 67-year-old male former AQ chewer 
and ex-smoker by a new enhanced topical ALA-PDT 
protocol. The early invasive OSCC lesion showed 
complete regression after a total of 18 treatments 
of topical ALA-PDT. In our previous studies, a topi-
cal ALA-PDT protocol was successfully used to treat 
36 OVH lesions, an extensive OVC lesion, and an 
extensive OVH lesion.10−16 The results of the present 
report confirmed that our new enhanced topical ALA-
PDT protocol also has good potential as an effec-
tive treatment modality for superficially invasive 
OSCC lesions.
The clinical appearance and treatment course of 
this superficially invasive OSCC lesion were compa-
rable to those of our previously reported extensive 
OVH lesion.16 Both lesions had a verrucous appear-
ance and showed complete regression after 18 treat-
ments with enhanced topical ALA-PDT. The incubation 
period (the time needed for the transformation of 
ALA into PpIX) was 1.5 hours, and the total light ex-
posure dose per treatment was 200 J/cm2 for both 
lesions. In addition, both lesions demonstrated nearly 
complete regression after eight treatments of the 
enhanced topical ALA-PDT. This suggests that dou-
bling the light dose may slightly shorten the treat-
ment course compared with that for our previously 
reported extensive OVC case. However, more-severe 
post-PDT pain was experienced by this early inva-
sive OSCC patient than by our previous OVC patient. 
Therefore, stronger analgesics were needed for this 
patient to control the post-PDT pain than for the 
previous OVC patient.
PDT with topically applied ALA is used to treat 
oral precancerous lesions like oral leukoplakia (OL) 
and OVH and cancerous lesions like OVC with prom-
ising clinical outcomes.7−16 Kubler et al.7 treated 
12 OL lesions with PDT after local application of 20% 
ALA cream and found a complete response (CR) in 
five, a partial response (PR) in four, and no response 
(NR) in three. Sieron et al.8,9 treated 17 OL lesions 
with PDT after topical application of 10% ALA oint-
ment or emulsion in two separate studies. A CR was 
observed in 14 of 17 OL lesions. Our previous studies 
showed that complete regression of 36 OVH lesions 
was achieved with fewer than seven treatments of 
topical ALA-PDT once a week.14 However, for an ex-
tensive OVC or OVH lesion, more treatments are 
needed.15,16 Our previous studies revealed that top-
ical ALA-PDT is not very effective for OL lesion. The 
65 OL lesions treated with topical ALA-PDT once a 
week showed a CR in five, a PR in 33, and NR in 27. 
The 32 OL lesions treated with the same topical 
ALA-PDT twice a week demonstrated a CR in 11 and 
a PR in 21. The twice-a-week treatment modality 
had a better clinical outcome for OL lesions than 
the once-a-week modality.13 The need for 10 treat-
ments of PDT to eradicate the multiple residual OL 
lesions in this patients also indicates the relative 
difficulty of obtaining a CR with topical ALA-PDT with 
medium- and small-sized OVH lesions.14 However, 
the results of the above-mentioned investigations 
suggest that PDT with topical ALA may be an effective 
treatment modality for OVH and OVC lesions and may 
have a good potential to be used as a treatment of 
choice for OVC and superficially invasive OSCC lesions 
without regional or distant metastasis. Further stud-
ies are needed to assess whether the new enhanced 
topical ALA-PDT is more effective than the previ-
ously used topical ALA-PDT for treating OL lesions.
The successful clinical outcome for this early inva-
sive OSCC lesion treated by the new enhanced topical 
ALA-PDT may have been due to the ALA prepara-
tion, the specific topical ALA-PDT protocol used, and 
the characteristic clinical, histologic and biologic 
features of the lesion itself. The reasons why our spe-
cific ALA preparation and the topical ALA-PDT pro-
tocol used resulted in a successful clinical outcome 
for OVH lesions were previously described.11−14,16 
Similar reasons could be used to explain the suc-
cessful clinical outcome for this case as well. The 
verrucous appearance of the present lesion provided 
a large area for good retention of ALA on the surface, 
and the less keratotic epithelium of this lesion than 
OL lesions also provided a more permeable surface 
layer for good absorption of ALA into the oral epi-
thelial cells. Furthermore, malignant epithelial cells 
may retain more ALA than hyperplastic epithelial 
cells, and the thinner surface keratin layer may only 
have a minimal effect on reducing the light intensity. 
In addition, there are more epithelial cells in the cell 
division cycle in cancerous than in hyperplastic oral 
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lesions. Malignant epithelial cells in the cell division 
cycle are more susceptible to destruction by PDT-
generated singlet oxygen molecules and free radi-
cals than those epithelial cells not in the cell division 
cycle. The sufficient photosensitizer and light dose 
ultimately resulted in a good clinical outcome for 
this early invasive OSCC lesion.
In this case report, we succeeded in treating a 
superficially invasive OSCC with an enhanced proto-
col of topical ALA-PDT. Although further studies are 
needed to verify the true efficacy of this enhanced 
treatment protocol, we suggest that our enhanced 
topical ALA-PDT protocol has good potential to be 
used as a treatment of choice for an early invasive 
OSCC without regional or distant metastasis before 
the commencement of other effective therapies.
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